ReviewNutrients2018
The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD.
Review in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pre-Parathyroidectomy PTH as an Integrated Biomarker of Glandular Remodeling and Skeletal Turnover in Secondary Hyperparathyroidism.International journal of molecular sciences · 2026Review
- Serum 25(OH)D concentration and risk of all-cause and cause-specific mortality in patients with chronic kidney disease: systematic review and dose-response meta-analysis of observational cohort studies.Nutrition & metabolism · 2026Review
- Combination therapy with nutritional vitamin D and calcimimetics in secondary hyperparathyroidism: a mechanism-based approach to restoring PTH regulation.Frontiers in nutrition · 2026Review
- Association of 25(OH)D status with calcium metabolism, inflammation, and thyroid autoimmunity in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Review
- Advances in noninvasive diagnosis of renal osteodystrophy.Renal failure · 2025Review
- Comparison of biochemical markers and technetium 99m methoxyisobutylisonitrile imaging in primary and secondary hyperparathyroidism.Frontiers in endocrinology · 2023Article
- Effect of hemodialysis combined with calcitriol on cardiac function and BNP in patients with hyperparathyroidism secondary to nephropathy.American journal of translational research · 2023Article
- Biochemical spectrum of parathyroid hormone disorders in patients attending Tribhuvan University Teaching Hospital, Kathmandu, Nepal.SAGE open medicine · 2023Article
- Expression of risk genes linked to vitamin D receptor super-enhancer regions and their association with phenotype severity in multiple sclerosis.Frontiers in neurology · 2022Article
- Vitamin D for Recovery of COVID-19 in Patients With Chronic Kidney Disease.Frontiers in nutrition · 2022Review
- Klotho/FGF23 and Wnt in SHPT associated with CKDAmerican journal of translational research · 2022Article
- Indoxyl-Sulfate-Induced Redox Imbalance in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2021Review
- Dietary Habits, Vitamin and Mineral Supplements in Patients with Chronic Kidney Disease (CKD).Nutrients · 2020Article
- Effects of calcifediol supplementation on markers of chronic kidney disease-mineral and bone disorder in dogs with chronic kidney disease.Journal of veterinary internal medicine · 2020Article
- Endocrine myopathies: clinical and histopathological features of the major forms.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2020Review
- The role ofEJNMMI research · 2019Article
- Inflammation-Related Patterns in the Clinical Staging and Severity Assessment of Chronic Kidney Disease.Disease markers · 2019Article
- The influence of uremic toxins on low bone turnover disease in chronic kidney disease.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23 (FGF-23) expression that disturbs renal 1,25-dihydroxy vitamin D (1,25D) synthesis; thereby increasing parathyroid hormone (PTH) production. FGF-23 acts on the parathyroid gland (PTG) to increase 1α-hydroxylase activity and results in increase intra-gland 1,25D production that attenuates PTH secretion efficiently if sufficient 25D are available. Interesting, calcimimetics can further increase PTG 1α-hydroxylase activity that emphasizes the demand for nutritional vitamin D (NVD) under high PTH status. In addition, the changes in hydroxylase enzyme activity highlight the greater parathyroid 25-hydroxyvitmain D (25D) requirement in secondary hyperparathyroidism (SHPT); the higher proportion of oxyphil cells as hyperplastic parathyroid progression; lower cytosolic vitamin D binding protein (DBP) content in the oxyphil cell; and calcitriol promote vitamin D degradation are all possible reasons supports nutritional vitamin D (NVD; e.g., Cholecalciferol) supplement is crucial in SHPT. Clinically, NVD can effectively restore serum 25D concentration and prevent the further increase in PTH level. Therefore, NVD might have the benefit of alleviating the development of SHPT in early CKD and further lowering PTH in moderate to severe SHPT in dialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.